Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESO College Corner
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESO College Corner
Cancerworld Magazine > Articles by: Janet Fricker

Posts by author

Janet Fricker

227 posts
Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.
Gut microbiome positively influences abiraterone response in prostate cancer
View Post
  • News

Gut microbiome positively influences abiraterone response in prostate cancer

  • Janet Fricker
  • 5 November 2020

Abiraterone acetate (AA), an agent used in castrate-resistant prostate cancer, promotes a shift towards health-associated, anti-inflammatory gut commensal bacteria, finds a study in Nature Communications. “These findings clearly demonstrate that the gut microbiome is playing a role in treatment response,”…

View Post
A silver lining: Could changes forced by the pandemic point to better ways to conduct our clinical trials?
View Post
  • Articles
  • Policy

A silver lining: Could changes forced by the pandemic point to better ways to conduct our clinical trials?

  • Janet Fricker
  • 23 October 2020

Pragmatic adjustments to trial protocols were seen to be essential during the Covid-19 pandemic to avoid trials being abandoned or delayed. Most changes involved reducing the requirements for travelling to centralised trials centres and reducing the level of reporting requirements.…

View Post
Four steps to eliminating HPV-related cancers: a call for action
View Post
  • News

Four steps to eliminating HPV-related cancers: a call for action

  • Janet Fricker
  • 16 October 2020

A new report underlines that vaccination, screening, treatment and public awareness, provide the cornerstone for eliminating cancers linked to the human papillomavirus (HPV) in Europe. The report was published by The European Cancer Organisation, Brussels on 7th October. The report,…

View Post
Cancer deaths fall, health disparities persist, cancer research affected, reports AACR
View Post
  • News

Cancer deaths fall, health disparities persist, cancer research affected, reports AACR

  • Janet Fricker
  • 6 October 2020

The American Association for Cancer Research (AACR) annual Cancer Progress Report for 2020, published 23 September, portrays a mixed picture. On a positive note, the report features advances in cancer treatment and falls in cancer-related deaths; while on the negative…

View Post
Metastatic prostate cancer: cabazitaxel shows quality of life benefits over both abiraterone and enzalutamide
View Post
  • News

Metastatic prostate cancer: cabazitaxel shows quality of life benefits over both abiraterone and enzalutamide

  • Janet Fricker
  • 6 October 2020

In addition to previously reported survival benefits, the taxane cabazitaxel improved quality of life in patients with advanced metastatic prostate cancer compared to the androgen signalling targeted inhibitors abiraterone and enzalutamide, reports the latest analysis of the CARD trial (Fizazi…

View Post
Combined therapies offer the key to drug-resistant cancer
View Post
  • News

Combined therapies offer the key to drug-resistant cancer

  • Janet Fricker
  • 5 October 2020

For the first time, an investigator initiated phase 1b study tested the combination of the PARP inhibitor olaparib, and the AKT inhibitor capivasertib, and showed this combination was well tolerated and achieved durable responses in patients with treatment-refractory breast, ovarian…

View Post
New European Code of Cancer Practice defines patient rights along the cancer pathway
View Post
  • News

New European Code of Cancer Practice defines patient rights along the cancer pathway

  • Janet Fricker
  • 23 September 2020

The European Code of Cancer Practice was launched on 23rd September in Brussels by the European Cancer Organisation to empower citizens with 10 key ‘overarching’ rights and reduce cancer care inequalities across Europe. “This powerful new tool sets out the…

View Post
Preclinical model identifies predictors of checkpoint inhibitor response
View Post
  • News

Preclinical model identifies predictors of checkpoint inhibitor response

  • Janet Fricker
  • 22 September 2020

A study published in PNAS (Chen IX, et al. PNAS 2020) of a new mouse model has enabled the identification of distinct gene signatures that distinguish responders from non-responders to immune checkpoint blockade (ICB). “Our findings provide a general approach…

View Post
New transatlantic partnership to regain the momentum of cancer research
View Post
  • News

New transatlantic partnership to regain the momentum of cancer research

  • Janet Fricker
  • 9 September 2020

Building on the existing Cancer Research UK (CRUK) Grand Challenges initiative, a broader international collaboration has now been forged in partnership with the National Cancer Institute (NCI) in the US. This new Cancer Grand Challenges has been launched to seek…

View Post
ESMO provides first recommendations on use of next-generation sequencing in metastatic cancer
View Post
  • News

ESMO provides first recommendations on use of next-generation sequencing in metastatic cancer

  • Janet Fricker
  • 8 September 2020

Patients with metastatic non-squamous non-small-cell lung cancer (NSCLC), prostate cancers, ovarian cancers and cholangiocarcinoma should be offered next-generation sequencing (NGS) for profiling tumour samples, concludes an expert panel from the European Society for Medical Oncology (ESMO) in their review (Mosele…

View Post

Posts pagination

Previous 1 … 20 21 22 23 Next
search
CancerWorld #105 Download CancerWorld #104 Download CancerWorld #103 Download CancerWorld #102 Download CancerWorld #101 Download or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • How a Brain-Destroying Protein Became Cancer’s Ally: Alpha-Synuclein Emerges as a New Target in Melanoma
    • 4 July 2025
  • CancerWorld #105 (July 2025)
    • 2 July 2025
  • How a Chicken Egg Model Could Transform Pediatric Cancer Treatment in Canada
    • 20 June 2025
  • Microbiota-Derived Bile Acids as Androgen Receptor Antagonists Enhance Anti-Tumour Immunity
    • 19 June 2025
  • Strategies Needed to Prioritise Screening in Survivors of Childhood Cancer
    • 4 June 2025
Article
  • Suheir Rasul: Protecting Human Dignity
    • 4 July 2025
  • Equity:The Word That Shaped Her Career From The Lab To The White House:The Story Of Catharine Young
    • 4 July 2025
  • Curious, Rejected,Accepted: An ESO Fellow’s Road to Becoming an Oncologist
    • 3 July 2025
Social

Would you follow us ?

Contents
  • Suheir Rasul: Protecting Human Dignity
    • 4 July 2025
  • Equity:The Word That Shaped Her Career From The Lab To The White House:The Story Of Catharine Young
    • 4 July 2025
  • Curious, Rejected,Accepted: An ESO Fellow’s Road to Becoming an Oncologist
    • 3 July 2025
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESO College Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.